CareDx, Inc. (CDNA) Stock
2 members of Congress disclosed 14 trades in CDNA since 2019: 6 purchases and 8 sales, most recently Daniel Goldman (sale, Mar 6, 2023). 6 of the hedge funds AlphaScala tracks reported CDNA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $55.68M.
Which members of Congress traded CareDx, Inc. (CDNA)?
Most recent: Daniel Goldman (sale, Mar 6, 2023); records start Mar 11, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-03-06 | sale | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-03-02 | purchase | $15k – $50k |
| Tom Malinowski D-NJ · House | 2021-01-11 | partial sale | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-01-08 | partial sale | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-01-06 | partial sale | $15k – $50k |
| Tom Malinowski D-NJ · House | 2020-12-29 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-12-23 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-12-07 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CDNA political trades →Which hedge funds own CDNA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 1.95M | $55.68M | -12% |
| Renaissance Technologies Jim Simons (founder) | 1.24M | $35.42M | +5% |
| D.E. Shaw David Shaw | 1.14M | $32.42M | +30% |
| Citadel Ken Griffin | 107K | $3.05M | +27% |
| Millennium Management Israel Englander | 74K | $2.10M | NEW |
| Marshall Wace | 18K | $510.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are CareDx, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 5, 26 | Bickerstaff George | Director | SELL | 20.0K | $926K |
| Aug 5, 26 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 2.2K | $101K |
| Aug 5, 26 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 500 | $23K |
| Aug 4, 26 | Cournoyer Christine | Director | SELL | 16.0K | $751K |
| Aug 4, 26 | Goldberg Michael | Director | SELL | 44.7K | $2.1M |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →CDNA price chart
Powered by TradingViewWhat does CareDx, Inc. do?
CareDx Inc. is a leading precision medicine company that discovers, develops, and commercializes clinically differentiated diagnostic solutions for transplant patients and caregivers. It specializes in genomics-based testing services, including AlloSure Kidney and AlloSure Heart for donor-derived cell-free DNA surveillance in kidney and heart transplant patients, AlloMap Heart as a gene expression test for heart transplants, and AlloSure Lung for lung transplants. The company also provides high-quality lab products like HLA typing solutions such as AlloSeq Tx, Olerup SSP, and AlloSeq cfDNA to improve donor-recipient matching for organs and stem cells. Complementing these, CareDx Inc. offers digital transplant solutions through platforms like Ottr for patient surveillance and EMR integration, XynManagement for quality improvement and care coordination, and mobile apps such as AlloCare and Transplant Hero for medication adherence and health monitoring. Operating primarily in the healthcare sector with a focus on testing services, products, patient solutions, and pharma services, CareDx Inc. supports transplant centers, clinicians, and biopharma partners across the pre- and post-transplant journey. Founded in 1998 and headquartered in Brisbane, California, it plays a key role in advancing transplant outcomes through non-invasive molecular testing and innovative technologies.